The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: A lifetime multi-cohort model

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Van Bellinghen, Laure Anne ^a   Meier, Genevieve ^b   Van Vlaenderen, Ilse ^a  

^a CHESS ^*  (Belgium)

^b GSK   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG DOSAGE FORM COMPARISON; HEALTH CARE COST; HUMAN; INFANT; INFLUENZA A; INFLUENZA B; INFLUENZA VACCINATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MIDDLE AGED; PRESCHOOL CHILD; PROBABILITY; QUALITY OF LIFE; SCHOOL CHILD; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; UNITED KINGDOM; VERY ELDERLY; VIRUS LOAD; YOUNG ADULT;

EID: 84902576162     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098437     Document Type: Article

References (55)

1. Department of Health (2012) The Green Book. Chapter 19: Influenza. Available: https://www.wp.dh.gov.uk/immunisation/files/2012/07/Green-Book- Chapter-19-v4-71.pdf. Accessed 16 Nov. 2012.
2. Pitman RJ, Melegaro A, Gelb D, Siddiqui MR, Gay NJ, et al. (2007) Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 54: 530-538. (Pubitemid 46731221)
3. Belshe RB (2010) The need for quadrivalent vaccine against seasonal influenza. Vaccine 28 Suppl 4: D45-D53.
4. Irving SA, Patel DC, Kieke BA, Donahue JG, Vandermause MF, et al. (2012) Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004-2005 through 2007-2008. Influenza Other Respir Viruses 6: 37-43.
5. Knipe DM, Howley PM. (2007) Orthomyxoviruses. In: Palese P, Shaw ML, editors. Fields Virology.Philadelphia, PA: Lippincott Williams & Wilkins.
6. Thompson WW, Weintraub E, Dhankhar P, Cheng PY, Brammer L, et al. (2009) Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respir Viruses 3: 37-49.
7. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, et al. (2012) Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 54: 1427-1436.
8. Health Protection Agency (HPA) (2012) Seasonal influenza: epidemiological data. Available: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/ SeasonalInfluenza/EpidemiologicalData/. Accessed 7 Nov. 2012.
9. Domachowske J, Pankow-Culot H, Bautista M, Feng Y, Claeys C, et al. Immunogenicity and safety profile of a candidate inactivated quadrivalent influenza vaccine in children: a randomized controlled study. Presented at Influenza Vaccine for the World (IVW), Valencia, Spain, 9-12 October 2012. 2012.
10. Kieninger D, Lin WY, Yu CJ, Bayas JM, Gabor JJ, et al. Immunogenicity and safety profile of a candidate inactivated quadrivalent influenza vaccine in adults and the elderly: a randomized controlled study. Presented at Influenza Vaccine for the World (IVW), Valencia, Spain, 9-12 October 2012. 2012.
11. Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Doniz CA, Chandrasekaran V, et al. (2012) Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus two trivalent influenza vaccines: a randomized controlled trial in adults. Presented at ID Week, San Diego, CA, USA, 17-21 October 2012.
12. Joint Committee on Vaccination and Immunisation (JCVI) Minute of the meeting on Wednesday 13 June 2012 10.30am-4pm. 13-6-2012.
13. Joint Committee on Vaccination and Immunisation (JCVI) JCVI statement on the annual influenza vaccination programme - extension of the programme to children. 25-7-2012.
14. Summary of product characteristics, live attenuated influenza vaccine (2013) Available: http://www.medicines.org.uk/EMC/medicine/25084/SPC/.Ac- Accessed 12 Dec. 2013.
15. Department of Health (2013) The Green Book. Chapter 19: Influenza. Available: https://www.gov.uk/government/uploads/system/uploads/attachment-data/ file/239268/Green-Book-Chapter-19-v5-2-final.pdf. Accessed 3 Apr. 2014.
16. Burch J, Paulden M, Conti S, Stock C, Corbett M, et al. (2009) Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess 13: 1-iv.
17. Burls A, Clark W, Stewart T, Preston C, Bryan S, et al. (2002) Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol Assess 6: 1-87.
18. Burls A, Jordan R, Barton P, Olowokure B, Wake B, et al. (2006) Vaccinating healthcare workers against influenza to protect the vulnerable-is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation. Vaccine 24: 4212-4221. (Pubitemid 44308224)
19. Griffin AD, Perry AS, Fleming DM (2001) Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics 19: 293-301. (Pubitemid 32230943)
20. Reisinger K, Greene G, Aultman R, Sander B, Gyldmark M (2004) Effect of influenza treatment with oseltamivir on health outcome and costs in otherwise healthy children. Clin Drug Investig 24: 395-407. (Pubitemid 38951791)
21. Sander B, Gyldmark M, Hayden FG, Morris J, Mueller E, et al. (2005) Influenza treatment with neuraminidase inhibitors: Cost-effectiveness and cost-utility in healthy adults in the United Kingdom. European Journal of Health Economics 6: 244-252. (Pubitemid 41638848)
22. Sander B, Hayden FG, Gyldmark M, Garrison LP Jr (2006) Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. Pharmacoeconomics 24: 373-386.
23. Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, et al. (2009) Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): A systematic review and economic evaluation. Health Technology Assessment 13: iii-148.
24. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, et al. (2003) Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technology Assessment 7.
25. Sander B, Gyldmark M, Aultman R, Aoki F (2004) Impact on health outcome and costs of influenza treatment with oseltamivir in elderly and high-risk patients. J Med Econ 7: 67-83. (Pubitemid 39186621)
26. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186. (Pubitemid 36068705)
27. National Institute for Health and Clinical Excellence (2011) Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza. Available: http://www.nice.org.uk/nicemedia/live/12060/42037/42037.pdf. Accessed 28 Feb. 2012.
28. National Institute for Health and Clinical Excellence (2011) Amantadine, oseltamivir and zanamivir for the treatment of influenza. Available: http://www.nice.org.uk/nicemedia/live/11774/43268/43268.pdf. Accessed 28 Feb. 2012.
29. Office for National Statistics (2011) Population estimates for the UK, England and Wales, Scotland and Northern Ireland - Estimated resident population mid-2010 by single year of age and sex in the United Kingdom. Available: http://www.statistics.gov.uk/statbase/Product.asp?vlnk=15106. Accessed 23 Feb. 2012.
30. Daley AJ, Nallusamy R, Isaacs D (2000) Comparison of influenza A and influenza B virus infection in hospitalized children. J Paediatr Child Health 36: 332-335. (Pubitemid 30618456)
31. Hite LK, Glezen WP, Demmler GJ, Munoz FM (2007) Medically attended pediatric influenza during the resurgence of the Victoria lineage of influenza B virus. Int J Infect Dis 11: 40-47. (Pubitemid 44937651)
32. National Institute for Health and Clinical Excellence (2007) Incorporating health economics in guidelines and assessing resource impact. Available: http://www.nice.org.uk/niceMedia/pdf/GuidelinesManualChapter8.pdf.
33. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V (2008) Vaccines for preventing influenza in healthy children. CD004879, 1-230. John Wiley & Sons, Ltd. Cochrane Database of Systematic Reviews.
34. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer G, Al-Ansary L, et al. (2010) Vaccines for preventing influenza in healthy adults. CD001269, 1-82. John Wiley & Sons, Ltd. Cochrane Database of Systematic Reviews.
35. Jefferson T, Di Pietrantonj C, Al-Ansary L, Ferroni E, Thorning S, et al. (2010) Vaccines for preventing influenza in the elderly. CD004876, 1-199. John Wiley & Sons, Ltd. Cochrane Database of Systematic Reviews.
36. Meier CR, Napalkov PN, Wegmuller Y, Jefferson T, Jick H (2000) Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. European Journal of Clinical Microbiology & Infectious Diseases 19: 834-842.
37. Rothberg MB, Bellantonio S, Rose DN (2003) Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med 139: 321-329.
38. Department of Health (2011) NHS trust reference cost schedules (Appendix NSRC01). Available: http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH-123459.
39. HPA (2011) Influenza vaccination uptake monitoring on behalf of the Department of Health. Available: http://www.hpa.org.uk/Topics/ InfectiousDiseases/InfectionsAZ/SeasonalInfluenza/EpidemiologicalData/ 15influsInfluenzavaccinationuptakemonitoring/.
40. Personal Social Services Research Unit 2010 (2011) Unit Costs of Health and Social Care 2010. Available: http://www.pssru.ac.uk/pdf/uc/uc2010/uc2010. pdf.
41. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, et al. (2013) Effect of influenza vaccination against mismatched strains: A systematic review and metaanalysis. BMC Medicine [[accepted]].
42. Osterholm MT, Kelley NS, Sommer A, Belongia EA (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12: 36-44.
43. DiazGranados CA, Denis M, Plotkin S (2012) Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine 31: 49-57.
44. Office for National Statistics (2011) Interim Life Tables, United Kingdom, 1980-82 to 2007-09. Available: http://www.ons.gov.uk/ons/publications/ re-reference-tables.html?edition= tcm%3A77-61850.
45. Office for National Statistics (2011) Population estimates for the UK, England and Wales, Scotland and Northern Ireland - Mid 2008. Available: http://www.ons.gov.uk/ons/publications/all-releases.html?definition=tcm: 77-22371. Accessed 27 Feb. 2012.
46. Fleming DM, Elliot AJ (2006) Estimating the risk population in relation to influenza vaccination policy. Vaccine 24: 4378-4385.
47. Department of Health (2011) The seasonal flu immunisation programme 2011/12. Available: http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/ documents/digitalasset/dh-128175.pdf.
48. Royal Pharmaceutical Society British National Formulary No.62. (2011).
49. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, et al. (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 6: 9-17. (Pubitemid 36228345)
50. Rawlins M, Barnett D, Stevens A (2010) Pharmacoeconomics: NICE's approach to decision-making. Br J Clin Pharmacol 70: 346-349.
51. Reed C, Meltzer MI, Finelli L, Fiore A (2012) Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 30: 1993-1998.
52. Public Health England (2013) PHE guidance on use of antiviral agents for the treatment and prophylaxis of influenza. Version v4.1. Available: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1317140666783. Accessed 4 Apr. 2014.
53. Prosser LA, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, et al. (2006) Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis 12: 1548-1558. (Pubitemid 44570897)
54. Smyth A (2002) Pneumonia due to viral and atypical organisms and their sequelae. Br Med Bull 61: 247-262.
55. Jain VK, Rivera L, Zaman K, Espos RA Jr, Sirivichayakul C, et al. (2013) Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med 369: 2481-2491.